Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug, CM-101, in primary sclerosing cholangitis, PSC, was presented in an oral Distinguished Abstract Plenary session at Digestive Disease Week, DDW 2025, in San Diego, California. Paul J. Pockros, MD, Director, Liver Disease Center Scripps Clinic and Director of SC Liver Research Consortium, who was a SPRING trial investigator, presented the nebokitug data. He noted, “PSC is a potentially devastating progressive disease that lacks any FDA-approved therapies. The data from the SPRING trial are very encouraging, showing that nebokitug appears safe and well-tolerated over 48 weeks of treatment. Notably, patients with more active moderate to severe disease showed sustained improvements in multiple biomarkers associated with disease progression. We believe these findings suggest that nebokitug may have disease-modifying potential and support developing nebokitug 20 mg/kg in a Phase 3 clinical study in patients with PSC.”